


Accepted Manuscript

Dilemmas, confusion, and misconceptions related to small airways directed therapy

Federico Lavorini, Ph.D, Søren Pedersen, Ph.D, Omar S. Usmani, Ph.D



PII: S0012-3692(16)53753-2

DOI: [10.1016/j.chest.2016.07.035](https://doi.org/10.1016/j.chest.2016.07.035)

Reference: CHEST 599

To appear in: *CHEST*

Received Date: 18 March 2016

Revised Date: 20 July 2016

Accepted Date: 30 July 2016

Please cite this article as: Lavorini F, Pedersen S, Usmani OS, on behalf of the Aerosol Drug Management Improvement Team, Dilemmas, confusion, and misconceptions related to small airways directed therapy, *CHEST* (2016), doi: 10.1016/j.chest.2016.07.035.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Dilemmas, confusion, and misconceptions related to small airways directed therapy

Federico Lavorini¹ Ph.D., Søren Pedersen² Ph.D., Omar S. Usmani³ Ph.D.,

on behalf of the Aerosol Drug Management Improvement Team.

1, Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy.

2, University of Southern Denmark, Pediatric Research Unit, Kolding Hospital, Kolding, Denmark.

3, National Heart & Lung Institute, Imperial College London & Royal Brompton Hospital, Airways Disease Section, London, UK.

Corresponding author:

Federico Lavorini, M.D., Ph.D.

Department of Experimental and Clinical Medicine,

Careggi University Hospital.

Largo Brambilla 3, 50134, Florence, Italy

Email: federico.lavorini@unifi.it

Running title: small airways directed therapy

Word count: 4042

Conflict of interest statement:

FL reports personal fees and honoraria for speaking and advisory boards from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Teva, Zentiva outside the submitted work

SP reports fees for consultancies or speaking from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Sandoz, outside the submitted work.

OSU. reports grants from AstraZeneca, Chiesi, GlaxoSmithKline, Prosonix, Sandoz, Takeda, Zentiva, personal fees from Aerocrine, Boehringer Ingelheim, Chiesi, Napp, Mundipharma, and Sandoz, outside the submitted work.

All authors are member of the Aerosol Drug Management Improvement Team, a non-profit European consortium of physicians with clinical and research expertise on the topic of inhaled therapy for respiratory diseases.

Download English Version:

<https://daneshyari.com/en/article/5600465>

Download Persian Version:

<https://daneshyari.com/article/5600465>

[Daneshyari.com](https://daneshyari.com)